Evommune

Goal disorientation and lack of vision
Biotech

Evommune gives up on dermatitis drug after another ph. 2 fail

Evommune’s MRGPRX2 antagonist flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for itch-related conditions.
James Waldron Sep 9, 2026 4:04am
Graphic image of an arrow nailing the bullseye of a target

Evommune's Dupixent-like eczema data drive 75% stock rally

Feb 10, 2026 9:31am
bullish sentiment

Biotech’s top 5 stock picks for 2026: analyst

Dec 23, 2025 10:05am
new york stock exchange

Inflammation biotech Evommune heads to NYSE with $150M IPO

Nov 6, 2025 7:00am
IPO art

Evommune prices IPO amid government shutdown

Oct 30, 2025 12:34pm
IPO initial public offering markets raise financing

Inflammation biotech Evommune eyes IPO to fund dermatitis trials

Oct 10, 2025 6:35am